These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The relationship between genetic liver fat and coronary heart disease is explained by apoB-containing lipoproteins. Björnson E; Adiels M; Bergström G; Gummesson A Atherosclerosis; 2024 Jan; 388():117397. PubMed ID: 38102060 [TBL] [Abstract][Full Text] [Related]
7. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. Burgess S; Ference BA; Staley JR; Freitag DF; Mason AM; Nielsen SF; Willeit P; Young R; Surendran P; Karthikeyan S; Bolton TR; Peters JE; Kamstrup PR; Tybjærg-Hansen A; Benn M; Langsted A; Schnohr P; Vedel-Krogh S; Kobylecki CJ; Ford I; Packard C; Trompet S; Jukema JW; Sattar N; Di Angelantonio E; Saleheen D; Howson JMM; Nordestgaard BG; Butterworth AS; Danesh J; JAMA Cardiol; 2018 Jul; 3(7):619-627. PubMed ID: 29926099 [TBL] [Abstract][Full Text] [Related]
8. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. Ference BA; Kastelein JJP; Ray KK; Ginsberg HN; Chapman MJ; Packard CJ; Laufs U; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Nicholls SJ; Bhatt DL; Sabatine MS; Catapano AL JAMA; 2019 Jan; 321(4):364-373. PubMed ID: 30694319 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. Richardson TG; Sanderson E; Palmer TM; Ala-Korpela M; Ference BA; Davey Smith G; Holmes MV PLoS Med; 2020 Mar; 17(3):e1003062. PubMed ID: 32203549 [TBL] [Abstract][Full Text] [Related]
10. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118 [TBL] [Abstract][Full Text] [Related]
11. Quantifying the contribution of lipoprotein(a) to all apoB containing particles. Chilazi M; Zheng W; Park J; Marvel FA; Khoury S; Jones SR; Martin SS J Clin Lipidol; 2022; 16(2):220-226. PubMed ID: 35241398 [TBL] [Abstract][Full Text] [Related]
12. Rare Protein-Truncating Variants in APOB, Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease. Peloso GM; Nomura A; Khera AV; Chaffin M; Won HH; Ardissino D; Danesh J; Schunkert H; Wilson JG; Samani N; Erdmann J; McPherson R; Watkins H; Saleheen D; McCarthy S; Teslovich TM; Leader JB; Lester Kirchner H; Marrugat J; Nohara A; Kawashiri MA; Tada H; Dewey FE; Carey DJ; Baras A; Kathiresan S Circ Genom Precis Med; 2019 May; 12(5):e002376. PubMed ID: 30939045 [TBL] [Abstract][Full Text] [Related]
13. Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. Lamina C; Kronenberg F; JAMA Cardiol; 2019 Jun; 4(6):575-579. PubMed ID: 31017618 [TBL] [Abstract][Full Text] [Related]
14. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Pischon T; Girman CJ; Sacks FM; Rifai N; Stampfer MJ; Rimm EB Circulation; 2005 Nov; 112(22):3375-83. PubMed ID: 16316964 [TBL] [Abstract][Full Text] [Related]
15. Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease. Dron JS; Patel AP; Zhang Y; Jurgens SJ; Maamari DJ; Wang M; Boerwinkle E; Morrison AC; de Vries PS; Fornage M; Hou L; Lloyd-Jones DM; Psaty BM; Tracy RP; Bis JC; Vasan RS; Levy D; Heard-Costa N; Rich SS; Guo X; Taylor KD; Gibbs RA; Rotter JI; Willer CJ; Oelsner EC; Moran AE; Peloso GM; Natarajan P; Khera AV JAMA Cardiol; 2023 Mar; 8(3):258-267. PubMed ID: 36723951 [TBL] [Abstract][Full Text] [Related]
16. Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease. Pencina KM; Pencina MJ; Lawler PR; Engert JC; Dufresne L; Ridker PM; Thanassoulis G; Mora S; Sniderman AD Clin Chem; 2023 Jan; 69(1):48-55. PubMed ID: 36331823 [TBL] [Abstract][Full Text] [Related]
17. Effects of apolipoprotein B on lifespan and risks of major diseases including type 2 diabetes: a mendelian randomisation analysis using outcomes in first-degree relatives. Richardson TG; Wang Q; Sanderson E; Mahajan A; McCarthy MI; Frayling TM; Ala-Korpela M; Sniderman A; Smith GD; Holmes MV Lancet Healthy Longev; 2021 Jun; 2(6):e317-e326. PubMed ID: 34729547 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Lp[a] and other independent risk factors for CHD in Asian Indians and their USA counterparts. Hoogeveen RC; Gambhir JK; Gambhir DS; Kimball KT; Ghazzaly K; Gaubatz JW; Vaduganathan M; Rao RS; Koschinsky M; Morrisett JD J Lipid Res; 2001 Apr; 42(4):631-8. PubMed ID: 11290835 [TBL] [Abstract][Full Text] [Related]
20. Discordance between lipoprotein (a) and LDL-cholesterol levels in cardiovascular risk assessment in apparently healthy subjects. Bergmann K; Stefanska A; Krintus M; Sypniewska G Nutr Metab Cardiovasc Dis; 2023 Jul; 33(7):1429-1436. PubMed ID: 37169665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]